Regentis Biomaterials Company Profile - aVenture Research
Regentis Biomaterials
Regentis Biomaterials makes GelrinC, a cell-free off-the-shelf hydrogel implant that surgeons cure into the knee to treat articular cartilage injuries.
Regentis Biomaterials develops degradable hydrogel implants for orthopedic tissue repair as a manufacturer of hydrogels for cartilage and bone repair. Its Gelrin platform combines polyethylene glycol diacrylate and denatured fibrinogen into a matrix, and its lead product GelrinC is a cell-free, off-the-shelf hydrogel cured into a knee implant for articular cartilage injuries.
Gelrin is applied as a liquid that fills the entire tissue defect, then is eroded and resorbed over time in the body through gradual surface degradation. GelrinC holds CE mark approval as a device in Europe, and the company runs clinical trials in the United States toward a PMA submission.